Bausch Health Companies Future Growth

Future criteria checks 3/6

Bausch Health Companies's revenue is forecast to decline at 0.5% per annum while its annual earnings are expected to grow at 112.5% per year. EPS is expected to grow by 121.5% per annum.

Key information

112.5%

Earnings growth rate

121.50%

EPS growth rate

Pharmaceuticals earnings growth	14.3%
Revenue growth rate	-0.5%
Future return on equity	n/a
Analyst coverage	Good
Last updated	14 May 2025

Recent future growth updates

Recent updates

There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise

Oct 10

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Sep 19

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Aug 06

2 Red Alerts On Bausch Health Companies

Jul 25

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

May 21

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

May 07

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Feb 24

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Nov 30

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Nov 01

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Sep 24

Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Jul 24

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

Jul 06

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Jun 07

Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Apr 18

Earnings and Revenue Growth Forecasts

NYSE:BHC - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	10,493	N/A	2,841	1,676	4
12/31/2026	10,293	473	2,108	1,733	6
12/31/2025	10,011	257	1,663	1,540	6
3/31/2025	9,731	-40	1,216	1,597	N/A
12/31/2024	9,625	-46	1,257	1,597	N/A
9/30/2024	9,474	-178	1,009	1,386	N/A
6/30/2024	9,202	-471	911	1,263	N/A
3/31/2024	8,966	-455	785	1,089	N/A
12/31/2023	8,757	-592	760	1,032	N/A
9/30/2023	8,542	-963	893	1,117	N/A
6/30/2023	8,350	-186	-665	-428	N/A
3/31/2023	8,150	-357	-773	-511	N/A
12/31/2022	8,124	-225	-996	-728	N/A
9/30/2022	8,127	254	-1,434	-1,179	N/A
6/30/2022	8,192	43	384	648	N/A
3/31/2022	8,325	-407	648	920	N/A
12/31/2021	8,434	-948	1,143	1,426	N/A
9/30/2021	8,451	-1,170	1,512	1,796	N/A
6/30/2021	8,478	-1,287	1,190	1,488	N/A
3/31/2021	8,042	-1,018	988	1,293	N/A
12/31/2020	8,027	-560	802	1,111	N/A
9/30/2020	8,038	-1,923	641	951	N/A
6/30/2020	8,109	-2,043	899	1,210	N/A
3/31/2020	8,597	-1,888	1,046	1,349	N/A
12/31/2019	8,601	-1,788	1,223	1,501	N/A
9/30/2019	8,498	-616	1,329	1,586	N/A
6/30/2019	8,425	-917	1,386	1,593	N/A
3/31/2019	8,401	-1,619	1,241	1,476	N/A
12/31/2018	8,380	-4,148	N/A	1,501	N/A
9/30/2018	8,422	-3,291	N/A	1,760	N/A
6/30/2018	8,505	-1,640	N/A	1,728	N/A
3/31/2018	8,610	-805	N/A	1,774	N/A
12/31/2017	8,724	2,404	N/A	2,290	N/A
9/30/2017	8,964	1,376	N/A	2,224	N/A
6/30/2017	9,224	-1,143	N/A	2,304	N/A
3/31/2017	9,411	-1,407	N/A	2,484	N/A
12/31/2016	9,674	-2,409	N/A	2,087	N/A
9/30/2016	10,024	-2,280	N/A	2,172	N/A
6/30/2016	10,332	-1,013	N/A	2,360	N/A
3/31/2016	10,644	-764	N/A	2,323	N/A
12/31/2015	10,442	-292	N/A	2,257	N/A
9/30/2015	9,906	596	N/A	2,476	N/A
6/30/2015	9,175	822	N/A	2,336	N/A
3/31/2015	8,484	1,001	N/A	2,302	N/A
12/31/2014	8,200	881	N/A	2,312	N/A
9/30/2014	8,043	502	N/A	1,759	N/A
6/30/2014	7,529	-746	N/A	1,342	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BHC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: BHC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BHC is expected to become profitable in the next 3 years.

Revenue vs Market: BHC's revenue is expected to decline over the next 3 years (-0.5% per year).

High Growth Revenue: BHC's revenue is forecast to decline over the next 3 years (-0.5% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BHC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/23 21:06
End of Day Share Price	2025/05/23 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bausch Health Companies Inc. is covered by 39 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Douglas Tsao	Barclays
Ardalan Arfaei	BMO Capital Markets Equity Research
Robert Hazlett	BMO Capital Markets U.S. (Historical)

Bausch Health Companies Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target decreased by 7.1% to US$7.67

Price target increased by 23% to US$10.86

Bausch Health Companies Inc. Provides Earnings Guidance for the Full Year 2025

Price target decreased by 7.0% to US$8.83

Price target increased by 7.1% to US$8.57

Forecast breakeven date pushed back to 2025

Recent updates

Refinancing And New Product Launches Will Unlock Future Possibilities

Price target decreased by 7.1% to US$7.67

First quarter 2025 earnings: EPS misses analyst expectations

Bausch Health Companies Inc. to Report Q1, 2025 Results on Apr 30, 2025

Price target increased by 23% to US$10.86

Bausch Health Companies Inc. Provides Earnings Guidance for the Full Year 2025

Bausch Health Q4 Earnings Recap (Reiterating Buy Rating)

Full year 2024 earnings: EPS exceeds analyst expectations

Revenues Working Against Bausch Health Companies Inc.'s (NYSE:BHC) Share Price

Bausch Health Companies Inc., Annual General Meeting, May 13, 2025

Price target decreased by 7.0% to US$8.83

Bausch Health Companies Inc. to Report Q4, 2024 Results on Feb 19, 2025

Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors

Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Price target increased by 7.1% to US$8.57

Forecast breakeven date pushed back to 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Price target decreased by 18% to US$7.79

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Executive VP & General Counsel exercised options and sold US$318k worth of stock

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Price target decreased by 11% to US$8.36

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

2 Red Alerts On Bausch Health Companies

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Price target decreased by 7.7% to US$9.56

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

First quarter 2024 earnings: EPS misses analyst expectations

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Price target increased by 10% to US$10.33

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall from profit to US$0.03 loss

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Consensus EPS estimates fall by 89%, revenue upgraded

New major risk - Negative shareholders equity

No longer forecast to breakeven

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Consensus EPS estimates fall by 31%

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Consensus EPS estimates fall from profit to US$0.49 loss

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Price target increased by 11% to US$9.50

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Executive VP & CFO exercised options to buy US$1.1m worth of stock.

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc